Ocular Therapeutix vs Tonix Pharmaceuticals
OCUL and TNXP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How OCUL and TNXP compare
Ocular Therapeutix is the larger company, worth 26 times as much as Tonix Pharmaceuticals ($1.4B against $51.6M).
Tonix Pharmaceuticals grew revenue faster over the last twelve months (318% versus −9.7% for Ocular Therapeutix).
Tonix Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −420% compared with −649% at Ocular Therapeutix.
Tonix Pharmaceuticals scores higher on the StockData Score (10 against 3 for Ocular Therapeutix), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | OCUL | TNXP |
|---|---|---|
| Size and price | ||
| Market cap | $1.4B | $51.6M |
| Share price | $6.21 | $3.01 |
| Change, 1 year | −46.0% | −83.0% |
| Change, 5 years | −7.2% | −100.0% |
| Beta (5Y) | 1.25 | 2.01 |
| Employees | 325 | 142 |
| StockData Score | ||
| Total score | 3 | 10 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 0 | 2 (better) |
| Performance score | 0 | 0 |
| Health score | 3 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 27.1× | 1.2× (better) |
| P/B | 3.1× | 0.3× (better) |
| FCF yield | −19.6% (better) | −329% |
| Fair value | $4.70 | $18.27 |
| Margin of safety | −32.2% | 83.5% (better) |
| Growth | ||
| Revenue growth (TTM) | −9.7% | 318% (better) |
| Revenue growth, 5Y average | 24.4% | – |
| Profitability | ||
| Gross margin | 87.3% | 89.3% (better) |
| Operating margin | −681% | −436% (better) |
| Net margin | −649% | −420% (better) |
| FCF margin | −530% | −395% (better) |
| Return on equity | −93.5% | −84.1% (better) |
| Return on invested capital | – | −388% |
| Financial health | ||
| Debt / equity | 0.17 (better) | 0.00 |
| Interest coverage | −30.6× | – |
| Current ratio | 9.12 (better) | 4.57 |
| Altman Z-score | 0.92 (better) | −6.62 |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −288% |
| Shareholder yield | 0.00% (better) | −288% |
| Ownership | ||
| Held by institutions | 94.4% | 54.6% |
| Held by insiders | 2.9% | 0.27% |
| Insider net buying, 12 months | −$2.5M | $479K (better) |
| Short interest, % of float | 13.6% | 19.4% |
Go deeper
- OCUL stock overview
- OCUL income statement
- OCUL valuation and score
- TNXP stock overview
- TNXP income statement
- TNXP valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.